Concomitant medications and circulating tumor cells: friends or foes?

ABSTRACT: The use of concomitant medications by patients with cancer is observed almost globally; however, little attention has been paid to this topic in the medical literature. Most clinical studies do not describe the type and duration of drugs used at the time of inclusion and during treatment or how these drugs may affect the experimental and/or standard therapy. Even less information has been published on the potential interaction between concomitant medications and tumor biomarkers. However, we do know that concomitant drugs can complicate cancer clinical trials and biomarker development, thus contributing to their interaction, leading to side effects, and resulting in suboptimal adherence to anticancer treatment. On the basis of these premises and moving from the study by Jurisova et al.<

SUBMITTER: Di Cosimo S 

PROVIDER: S-EPMC10099593 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature